Elon Musk said Neuralink is expected to begin human clinical trials in six months. This is a wireless device developed by his brain chip company. The aim is to enable disabled patients to move and communicate again.

Elon Musk expects Neuralink’s chip to begin human trials in six months

Elon Musk said on Wednesday he expects a wireless brain chip developed by his company Neuralink to begin human clinical trials in six months after the company missed earlier timelines set by him.

Elon Musk expects Neuralink to begin human trials in six months

Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.

The trial has an "adaptive" design and could quickly move from dozens of patients to eventually include thousands, Chief Scientific Officer George Yancopoulos told Reuters.

"If it goes perfectly well, within a week or two we will move to the second phase. Within a month or so of that we will have clear data that this is or isn't working. By the end of summer, we could have sufficient data for broad utilization."

<a href="https://www.wionews.com/world/covid-19-russia-supplies-antivirus-drug-to-hospitals-cases-cross-500000-305079">Also read|&nbsp;COVID 19: Russia supplies antivirus drug to hospitals; cases cross 500,000</a>

The dual antibody, called REGN-COV2, is being compared to a placebo treatment in hospitalized COVID-19 patients, and in COVID-19 patients who have symptoms but are not sick enough to be hospitalized. Regeneron also plans to study REGN-COV2 for preventing the infection in people at high-risk of exposure - such as healthcare workers - and in uninfected people with close exposure to someone who has tested positive for the virus.

Antibodies are proteins made by the body's immune system that recognize, bind and neutralize an invading virus. Regeneron's cocktail - which contains an antibody made by the company and a second isolated from humans who recovered from COVID-19 - is designed so that its two antibodies bind to the coronavirus' spike protein, limiting the ability of viruses to escape.

<a href="https://www.wionews.com/videos/remdesivir-prevents-covid-19-lung-damage-tested-on-macaque-monkeys-304914">Also watch:&nbsp;Remdesivir prevents COVID-19 lung damage: Tested on macaque monkeys</a>&nbsp;

Trial patients will be given a single intravenous infusion of REGN-COV2. In the prevention segments of the study, participants will be given smaller subcutaneous doses, Yancopoulus said. Investigators will be measuring patients' viral loads and keeping track of symptoms.

Regeneron said its treatment could be useful even if a COVID-19 vaccine is developed since the elderly and people with compromised immune systems often do not respond well to vaccines.

Yancopoulos said, even though Regeneron does not yet have proof that REGN-COV2 is effective, the company has cleared the way for production of the antibody compound at its New York manufacturing facility.

Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.

Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus. The trial has an "adaptive" design and could quickly move from dozens of patients to eventually include thousands, Chief Scientific Officer George Yancopoulos told Reuters. "If it goes perfectly well, within a week or two we will move to the second phase. Within a month or so of that we will have clear data that this is or isn't working. By the end of summer, we could have sufficient data for broad utilization." Also read| COVID 19: Russia supplies antivirus drug to hospitals; cases cross 500,000 The dual antibody, called REGN-COV2, is being compared to a placebo treatment in hospitalized COVID-19 patients, and in COVID-19 patients who have symptoms but are not sick enough to be hospitalized. Regeneron also plans to study REGN-COV2 for preventing the infection in people at high-risk of exposure - such as healthcare workers - and in uninfected people with close exposure to someone who has tested positive for the virus. Antibodies are proteins made by the body's immune system that recognize, bind and neutralize an invading virus. Regeneron's cocktail - which contains an antibody made by the company and a second isolated from humans who recovered from COVID-19 - is designed so that its two antibodies bind to the coronavirus' spike protein, limiting the ability of viruses to escape. Also watch: Remdesivir prevents COVID-19 lung damage: Tested on macaque monkeys Trial patients will be given a single intravenous infusion of REGN-COV2. In the prevention segments of the study, participants will be given smaller subcutaneous doses, Yancopoulus said. Investigators will be measuring patients' viral loads and keeping track of symptoms. Regeneron said its treatment could be useful even if a COVID-19 vaccine is developed since the elderly and people with compromised immune systems often do not respond well to vaccines. Yancopoulos said, even though Regeneron does not yet have proof that REGN-COV2 is effective, the company has cleared the way for production of the antibody compound at its New York manufacturing facility.

Regeneron begins human testing of COVID-19 antibody cocktail

&nbsp;Johnson &amp; Johnson moved up the start of human clinical trials for its experimental vaccine against the highly contagious coronavirus by two months to the second half of July, as the drugmaker rushes to develop a prevention for COVID-19, the company said on Wednesday.

The acceleration should allow J&amp;J to take part in the massive clinical trials program planned by the U.S. government, which aims to have an effective vaccine by year end.

J&amp;J shares rose nearly 2% to $148.69.

Last March, J&amp;J signed deals with the U.S. government to create enough manufacturing capacity to produce more than 1 billion doses of its vaccine through 2021, even before it has evidence that it works.

There are currently no U.S. approved treatments or vaccines for the virus. A vaccine is seen as essential to ending the pandemic that has infected more than 7.2 million people and killed over 412,000 globally, while battering economies worldwide.

J&amp;J initially expected safety trials to start in September. Chief Scientific Officer Paul Stoffels told Reuters the company has been working closely with its U.S. government partners to accelerate that timeline.

"Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development," Stoffels said in a statement on Wednesday.

J&amp;J's study will test the vaccine for safety and early signs of efficacy in 1,045 healthy volunteers aged 18 to 55 years, and in those aged 65 and older. The trial will take place in the United States and Belgium.

The company is also in talks with the National Institutes of Allergy and Infectious Diseases(NIAID) to start larger, late-stage trials ahead of schedule, depending on results of the early studies and regulatory approval.

The United States is planning to test a handful of coronavirus vaccine candidates in trials that will enroll up to 30,000 subjects with the aim of getting an answer on efficacy as quickly as possible. National Institutes of Health Director Dr. Francis Collins told Reuters that companies will need to complete their safety trials by the end of summer to be included in those studies.

Stoffels said last week that J&amp;J hopes to have results of its vaccine efficacy trials in the first quarter of 2021. He added that the company is "working hard to bring it back to the end of the year."

A lot will depend on how much virus is circulating at that time, he said.

"If you have an incidence of 1% a year versus 4% a year, it's totally different. And that's where these trials are so unpredictable," he said referring to the percentage of new cases occurring in the population at the time.

The company plans to test the vaccine in high-transmission regions within the United States. If the incidence is low, "we will complement that with international sites to make sure that we reach enough endpoints quickly to prove the vaccine works," Stoffels said.

Moderna Inc, which is working in close partnership with NIAID, has started testing its vaccine candidate in a 600-subject mid-stage trial. The company expects to begin late-stage trials in July.

Moderna's vaccine uses messenger RNA technology, an approach that has yet to produce any approved vaccines. J&amp;J is utilizing the same technology used to make its Ebola vaccine, which won European regulatory approval late last month.

There are about 10 coronavirus vaccines in human testing. Experts have said a safe and effective vaccine could take at least 12 to 18 months from the start of development, which would shave several years off the typical vaccine development timeline.

Johnson & Johnson moved up the start of human clinical trials for its experimental vaccine against the highly contagious coronavirus by two months to the second half of July, as the drugmaker rushes to develop a prevention for COVID-19, the company said on Wednesday.

Johnson & Johnson moved up the start of human clinical trials for its experimental vaccine against the highly contagious coronavirus by two months to the second half of July, as the drugmaker rushes to develop a prevention for COVID-19, the company said on Wednesday. The acceleration should allow J&J to take part in the massive clinical trials program planned by the U.S. government, which aims to have an effective vaccine by year end. J&J shares rose nearly 2% to $148.69. Last March, J&J signed deals with the U.S. government to create enough manufacturing capacity to produce more than 1 billion doses of its vaccine through 2021, even before it has evidence that it works. There are currently no U.S. approved treatments or vaccines for the virus. A vaccine is seen as essential to ending the pandemic that has infected more than 7.2 million people and killed over 412,000 globally, while battering economies worldwide. J&J initially expected safety trials to start in September. Chief Scientific Officer Paul Stoffels told Reuters the company has been working closely with its U.S. government partners to accelerate that timeline. "Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development," Stoffels said in a statement on Wednesday. J&J's study will test the vaccine for safety and early signs of efficacy in 1,045 healthy volunteers aged 18 to 55 years, and in those aged 65 and older. The trial will take place in the United States and Belgium. The company is also in talks with the National Institutes of Allergy and Infectious Diseases(NIAID) to start larger, late-stage trials ahead of schedule, depending on results of the early studies and regulatory approval. The United States is planning to test a handful of coronavirus vaccine candidates in trials that will enroll up to 30,000 subjects with the aim of getting an answer on efficacy as quickly as possible. National Institutes of Health Director Dr. Francis Collins told Reuters that companies will need to complete their safety trials by the end of summer to be included in those studies. Stoffels said last week that J&J hopes to have results of its vaccine efficacy trials in the first quarter of 2021. He added that the company is "working hard to bring it back to the end of the year." A lot will depend on how much virus is circulating at that time, he said. "If you have an incidence of 1% a year versus 4% a year, it's totally different. And that's where these trials are so unpredictable," he said referring to the percentage of new cases occurring in the population at the time. The company plans to test the vaccine in high-transmission regions within the United States. If the incidence is low, "we will complement that with international sites to make sure that we reach enough endpoints quickly to prove the vaccine works," Stoffels said. Moderna Inc, which is working in close partnership with NIAID, has started testing its vaccine candidate in a 600-subject mid-stage trial. The company expects to begin late-stage trials in July. Moderna's vaccine uses messenger RNA technology, an approach that has yet to produce any approved vaccines. J&J is utilizing the same technology used to make its Ebola vaccine, which won European regulatory approval late last month. There are about 10 coronavirus vaccines in human testing. Experts have said a safe and effective vaccine could take at least 12 to 18 months from the start of development, which would shave several years off the typical vaccine development timeline.

J&J moves up start of coronavirus vaccine human trials to July

Oxford university has started human trials for a potential COVID-19 vaccine. Two volunteers have been injected as part of the trial out of a group of 800.

They will be monitored for 48 hours. Scientists will then gradually start injecting more volunteers.&nbsp;

The team started research on a COVID-19 vaccine in February and hopes to have a vaccine ready by September.

Hundreds of Hong Kong students appeared for their final secondary school exams on Friday.

The students were asked to arrive early to have their temperatures checked and their desks were placed about 6 feet apart.

The number of cases in the city has come down. &nbsp;But social distancing measures remain in place.

On Monday, the city reported no new cases for the first time since early March.

Russia is all set to open a temporary hospital in St Petersburg for coronavirus patients by the end of the week.

The facility will have over 1,000 beds.

The Defence Ministry is building 16 brand new hospitals across the country which are expected to be ready by mid-May.

Wearing masks is now mandatory in Brazil's Rio de Janeiro to curb the spread of COVID-19.

To encourage people to follow the rule, the state authorities decorated about 40 statues with masks. Brazil has recorded over 49,000 confirmed cases.

On Thursday, demonstrators in Washington DC &nbsp;placed fake body bags outside the trump hotel. Expressing their anger against the mounting coronavirus death toll.&nbsp;

Chanting slogans like "Trump lies, people die!", the protesters called for trump's resignation over his handling of the crisis.

The United State's tally is now nearing 900,000 cases, and nearly 50,000 people have been killed by the virus.

Separated by a transparent plastic barrier, residents of a French nursing home reunited with their family members for the first time since the coronavirus outbreak.

The French government has relaxed restrictions on visits to retirement homes. 8,309 people have died from coronavirus-related illnesses in French nursing homes --- accounting for 60% of France's total death toll.

An auto-rickshaw resembling the coronavirus is on a mission in southern India.

Through loudspeaker announcements, it is spreading awareness in Chennai city on how littering and spitting contribute to the spread of the virus.

Street artist Banksy's famous mural &nbsp;"girl with a pierced eardrum" now has a COVID-19 facelift.

The mural now wears a blue surgical face mask. The mural was painted on a building in the artist's home city of Bristol in England in 2014. Whether the addition has been made by the artist is not known.

Oxford university has started human trials for a potential COVID-19 vaccine. Two volunteers have been injected as part of the trial out of a group of 800. They will be monitored for 48 hours.

Oxford university has started human trials for a potential COVID-19 vaccine. Two volunteers have been injected as part of the trial out of a group of 800. They will be monitored for 48 hours. Scientists will then gradually start injecting more volunteers. The team started research on a COVID-19 vaccine in February and hopes to have a vaccine ready by September. Hundreds of Hong Kong students appeared for their final secondary school exams on Friday. The students were asked to arrive early to have their temperatures checked and their desks were placed about 6 feet apart. The number of cases in the city has come down. But social distancing measures remain in place. On Monday, the city reported no new cases for the first time since early March. Russia is all set to open a temporary hospital in St Petersburg for coronavirus patients by the end of the week. The facility will have over 1,000 beds. The Defence Ministry is building 16 brand new hospitals across the country which are expected to be ready by mid-May. Wearing masks is now mandatory in Brazil's Rio de Janeiro to curb the spread of COVID-19. To encourage people to follow the rule, the state authorities decorated about 40 statues with masks. Brazil has recorded over 49,000 confirmed cases. On Thursday, demonstrators in Washington DC placed fake body bags outside the trump hotel. Expressing their anger against the mounting coronavirus death toll. Chanting slogans like "Trump lies, people die!", the protesters called for trump's resignation over his handling of the crisis. The United State's tally is now nearing 900,000 cases, and nearly 50,000 people have been killed by the virus. Separated by a transparent plastic barrier, residents of a French nursing home reunited with their family members for the first time since the coronavirus outbreak. The French government has relaxed restrictions on visits to retirement homes. 8,309 people have died from coronavirus-related illnesses in French nursing homes --- accounting for 60% of France's total death toll. An auto-rickshaw resembling the coronavirus is on a mission in southern India. Through loudspeaker announcements, it is spreading awareness in Chennai city on how littering and spitting contribute to the spread of the virus. Street artist Banksy's famous mural "girl with a pierced eardrum" now has a COVID-19 facelift. The mural now wears a blue surgical face mask. The mural was painted on a building in the artist's home city of Bristol in England in 2014. Whether the addition has been made by the artist is not known.

Coronavirus tracker: From human trials at Oxford to painted murals at Bristol!

human-trial

Human Trial, News on Human Trial, stories on Human Trial, articles on Human Trial, Human Trial stories at Wion, Human Trial news, Human Trial latest news